4 completed, 4 unknown, 3 recruiting, 3 terminated. 17 Phase 2, 4 Phase 1, 2 Phase 3.
Follow Oesophageal Cancer: new trials by email Literature Review of Oesophageal Cancer trials Research Report on Oesophageal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG - Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 300 | 2025-11-01 | 2025-11-18 |
| PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation - Esophageal Cancer, Oesophageal Cancer | Phase 2 | Recruiting | Medical College of Wisconsin | 50 | 2025-06-17 | 2026-07-28 |
| Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types [18F]AlF-FAPI-74 PET/CT - Oesophageal Cancer, Gastric Cancer | Phase 2 / Phase 3 | Recruiting | KU Leuven | 109 | 2025-02-06 | 2025-02-07 |
| A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C - Carcinoma, Hepatocellular, Gastric Adenocarcinoma | Phase 2 | Recruiting | National University Hospital, Singapore | 360 | 2024-11-25 | 2025-01-10 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis Hepatic Biopsy, BO-112 with pembrolizumab - Colorectal Cancer, Gastric Cancer | Phase 2 | Terminated | Highlight Therapeutics | 18 | 2020-06-17 | 2024-11-29 |
| A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer Olaparib - Oesophageal Cancer, Gastro-Oesophageal Junction Cancer | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 54 | 2019-07-02 | 2019-07-08 |
| Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab Durvalumab - Oesophageal Cancer | Phase 2 | Active not recruiting | Simon C Pacey, MD | 18 | 2018-10-30 | 2025-04-24 |
| A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer Nivolumab, Ipilimumab - Esophageal Cancer, Oesophageal Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 66 | 2018-02-21 | 2022-09-29 |
| BT1718 in Patients with Advanced Solid Tumours. BT1718 - Advanced Solid Tumours, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Cancer Research UK | 72 | 2018-01-24 | 2024-10-24 |
| A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer Durvalumab, Tremelimumab, SBRT - Head and Neck Squamous Cell Carcinoma, Lung Cancer | Phase 1 / Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 54 | 2017-06-20 | 2025-05-08 |
| Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Carboplatin, Paclitaxel, Cisplatin - Oesophageal Cancer | Phase 2 / Phase 3 | Unknown | Lisette Nixon | 584 | 2016-11-04 | 2018-10-25 |
| A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer donafenib tosilate tablets - Oesophageal Cancer | Phase 1 / Phase 2 | Terminated | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 19 | 2015-07-21 | 2023-06-15 |
| NY-ESO-1 T Cells in OG Cancer NY-ESO-1 T cells, cyclophosphamide, Fludarabine - Oesophageal Cancer | Phase 2 | Terminated | Fiona Thistlethwaite | 2 | 2014-10-01 | 2018-08-07 |
| Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF) - Oesophageal Cancer, Rectal Cancer | Phase 2 | Completed | Institut Paoli-Calmettes | 29 | 2014-04-01 | 2017-03-03 |
| A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer Oxaliplatin, Capecitabine, Carboplatin - Oesophageal Cancer | Phase 2 | Unknown | Lisette Nixon | 85 | 2013-10-01 | 2014-03-24 |
| Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours AZD 4547 - Gastric Cancer, Oesophageal Cancer | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 48 | 2012-09-01 | 2013-03-15 |
Esophageal Neoplasms (17) · Stomach Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Esophagitis (1) · Fibromatosis, Gingival, 2 (1) · Lethal Congenital Contracture Syndrome 2 (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Digestive System Diseases (17) · Digestive System Neoplasms (17) · Esophageal Diseases (17) · Gastrointestinal Diseases (17) · Gastrointestinal Neoplasms (17) · Head and Neck Neoplasms (17) · Neoplasms by Site (17) · Neoplasms (16) · Stomach Diseases (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma (3)
Capecitabine (3) · Carboplatin (2) · Oxaliplatin (2) · Paclitaxel (2) · Radiotherapy (2) · Surgical Procedures, Operative (2) · durvalumab (2) · BO-112 (1) · Cisplatin (1) · Cyclophosphamide (1) · Drug Therapy (1) · Heart Rate (1) · Induction Chemotherapy (1) · Interleukin-2 (1) · Ipilimumab (1)
Cancer Research UK (2) · Lisette Nixon (2) · Royal Marsden NHS Foundation Trust (2) · AIO-Studien-gGmbH (1) · Fiona Thistlethwaite (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Highlight Therapeutics (1) · Institut Paoli-Calmettes (1) · KU Leuven (1) · Medical College of Wisconsin (1) · National University Hospital, Singapore (1) · Shenyang Sunshine Pharmaceutical Co., LTD. (1) · Simon C Pacey, MD (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1)
United Kingdom (8) · Belgium (2) · China (2) · France (2) · Germany (1) · Italy (1) · Singapore (1) · Spain (1) · United States (1)
David Cunningham, MD FRCP (1) · Doctor Starling (1) · Jianming Xu, Doctor (1) · Johann de Bono, Prof (1) · Lindsay Puckett, MD (1) · Matthias Ebert, Prof. Dr. (1) · Simon Pacey (1) · Tom Crosby (1) · Vanesa Pons, MD, PhD (1) · Wei Peng Yong (1)
PMID 25880814, PMID 28335886, PMID 30871493, PMID 32768158, PMID 34157617, PMID 35623069, PMID 36098320, PMID 37409323, PMID 39097500, PMID 39313288, PMID 40012034
2015 (1), 2016 (1), 2017 (1), 2019 (1)